Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial - sprookjes - yvandenbroek - TriplyDB

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

http://www.wikidata.org/entity/Q28254031

about

Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond Advances and challenges in malaria vaccine development Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age The clinical development process for a novel preventive vaccine: An overview Malaria vaccine: a future hope to curtail the global malaria burden Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein Malaria: progress, perils, and prospects for eradication Genistein-supplemented diet decreases malaria liver infection in mice and constitutes a potential prophylactic strategy Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cells Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data.Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models.Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children.In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials.Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications.A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species.Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes.

P2860

Q20905953-3435BA74-1975-40A6-B35A-8A4969E25ED0 Q21032463-B7CAF892-75F1-4EA4-B9CB-8F6EB351CACA Q21032495-ED59DCD9-D543-4FCE-86E1-D14D77252CD9 Q21562479-9B2B0A77-8A77-49C4-8DC2-7C6408FF8A61 Q24628167-A085030B-CD60-4F7F-8FF9-07A4A0A50748 Q24648408-FA3D2823-3E9F-4CD6-AE90-4651B136BB90 Q24658073-A3097CE7-D3B5-427E-A577-9395222EFAC5 Q26770871-5FED2588-20BA-4618-8A31-2AA6072521E2 Q26996425-19F160B5-4CBF-482B-8610-604611CDEFC6 Q27310086-A0639D27-82BA-4F86-BF0A-AB4AC684E92D Q27485634-E5125918-03AA-46A0-A4A6-DFD8AB2788CE Q28473154-CE5EB73D-A0A5-484C-BF1D-B2D828E40287 Q28541281-D8EB6952-169C-49DB-BC8B-345C383DFA25 Q28730541-99CF590F-9FAF-4905-A7BE-824F81C1E7DD Q28731458-993C4156-A42E-444C-AC6C-7BB8DFDA4576 Q28740701-D0C951C6-8487-4B61-8D29-14D9809BB19D Q28741059-94AD355E-D6FD-4454-91E8-C76E0D21A3B2 Q28742596-D07953EE-D786-46A0-805E-CA10BDDE0B13 Q28744136-0234AD27-C5DC-488F-8D07-0B635F2D3D19 Q28744149-5ABDFBC9-7A7D-4F6F-8BD7-FFD38AE687AB Q28744573-5138EC7E-2375-4C3B-800A-54D2231BA588 Q28748565-3C12226F-0C76-41DA-AEDB-F05C80664055 Q30043830-73D54563-44C1-45BE-B951-60C789E38F00 Q30596414-682E07B8-8884-4E88-AC4D-D18112DCE200 Q30662529-BD523E49-2800-4094-9908-CAECB05A64CB Q30895708-1ABA23C0-8922-4ED4-8CCD-459DDD452086 Q30983587-0E823EFF-E9EC-4A01-9D70-77FAA11F826F Q33316023-271ED8DF-5D22-4B83-B6F9-76C229E03F6C Q33394245-F08522E6-591B-46FB-BE9E-AA67E9577455 Q33430011-9E8970F7-DCD4-4F7A-83FA-E42813D76642 Q33464933-78E7FBE8-25B2-4A55-B206-A3E2E05B46D9 Q33489512-B284621D-9381-463D-917E-798305152593 Q33512921-C2B01BB9-1E5D-4570-A98E-43FDD5BA10AC Q33517961-A65508E5-FF37-4385-A7EE-49317286ADD3 Q33521372-CD6FD3D0-77ED-41D4-AC98-D2EAA9DF5D59 Q33587443-154EB082-CE06-43AD-9282-4FFA0D3FAAB1 Q33846126-EB433CC4-20DB-4A3E-8DE6-591CECBCB0AC Q33859633-9CC2FBF9-7836-4B76-A7ED-ABB883890871 Q33892507-1FA5E54F-D4BC-484E-9EFF-AEEF79761652 Q33909124-AD1BEFE5-6EB2-43D0-889A-EBFE296F24C9

P2860

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

http://www.wikidata.org/entity/Q28254031

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Safety of the RTS,S/AS02D cand ...... d controlled phase I/IIb trial

@ast

Safety of the RTS,S/AS02D cand ...... d controlled phase I/IIb trial

@en

Safety of the RTS,S/AS02D cand ...... d controlled phase I/IIb trial

@nl

type

label

Safety of the RTS,S/AS02D cand ...... d controlled phase I/IIb trial

@ast

Safety of the RTS,S/AS02D cand ...... d controlled phase I/IIb trial

@en

Safety of the RTS,S/AS02D cand ...... d controlled phase I/IIb trial

@nl

prefLabel

Safety of the RTS,S/AS02D cand ...... d controlled phase I/IIb trial

@ast

Safety of the RTS,S/AS02D cand ...... d controlled phase I/IIb trial

@en

Safety of the RTS,S/AS02D cand ...... d controlled phase I/IIb trial

@nl

P1433

Q28254031-1F3E2A9F-ED42-48D7-AADC-96BC653F684B

P1476

Q28254031-42BB2903-2A22-4147-9985-18EBF8EF9A18

P2093

Q28254031-046FEF2B-366A-41F3-A9F9-CF5035E43319

Q28254031-0AC6F32A-E715-4607-9E03-A51CB910DB1D

Q28254031-2821CD63-4BA6-4974-B3E8-9ECF6A9E2641

Q28254031-2CE502CA-394F-4C2D-A0C6-A336A7315B22

Q28254031-2D0F9C2A-654D-4031-8B26-89868A3A1600

Q28254031-48956AF8-311A-4536-8006-6EAFA5D566C6

Q28254031-5A15A728-CCA7-47D9-9B8A-B3D8AFBD325B

Q28254031-5E32C3B6-8E54-4916-AE16-690230EF79E8

Q28254031-7DF9339E-EBDE-4258-99DB-6C0483336CC9

Q28254031-8200294F-5478-461E-868C-AC43EB6AE44D

P304

Q28254031-4F829336-B685-435F-8F3F-1583ED05D08A

P31

Q28254031-0814AABC-8666-445B-B0D3-3A9AE9AAE0A8

P3181

Q28254031-8920D5A5-0607-41C5-B8C6-4973A86B39C8

P356

Q28254031-90F41364-FC0C-4F05-B054-777A5B669B64

P407

Q28254031-A93485A6-301F-4C12-BD13-4AB9DCA01E3C

P433

Q28254031-1DF3D7CA-FC3A-4F4F-BBED-4A7C1DF89BD1

P478

Q28254031-0CD48723-2E5A-4E70-B21E-9A14A1C8B138

P50

Q28254031-37EE2840-2D75-4B37-AC24-146083BC9949

Q28254031-625358C5-1746-493C-B4CD-3297693D6B1B

Q28254031-A30790C5-3E86-4C27-AC25-6DBE4863E219

Q28254031-AED25B76-6B66-4A72-AEB9-CCD89FD03635

Q28254031-B52C06D1-37BD-4DE5-9DF9-E96F6423CE34

Q28254031-B5BBF842-5209-477C-9A4C-9A887433792B

Q28254031-CBFF22D1-B1CC-4EFA-8E79-F1EE7009BA7A

Q28254031-CC8A1387-AD28-4DD5-857A-998EB3F88B12

P577

Q28254031-7CC771D5-5C99-4540-838B-A35DBEC68C26

P698

Q28254031-1D53E7A1-6BF5-4201-994F-4E9BA26655F3

P921

Q28254031-28C11B03-1DAE-42A8-93B2-439C3E87B3FE

Q28254031-5D61E5FA-DFCF-4311-B6F5-271389CF3E13

Q28254031-F044D8D7-84D0-4163-B241-704670AD62A8

P3181

P356

S0140-6736(07)61542-6

P1433

P1476

Safety of the RTS,S/AS02D cand ...... d controlled phase I/IIb trial

@en

P2093

Amanda Leach

http://www.w3.org/2001/XMLSchema#string

Barbara Savarese

http://www.w3.org/2001/XMLSchema#string

Betuel Sigauque

http://www.w3.org/2001/XMLSchema#string

Eusebio Macete

http://www.w3.org/2001/XMLSchema#string

Joe Cohen

http://www.w3.org/2001/XMLSchema#string

John G McNeil

http://www.w3.org/2001/XMLSchema#string

M Nelia Manaca

http://www.w3.org/2001/XMLSchema#string

Marc Lievens

http://www.w3.org/2001/XMLSchema#string

Marie-Ange Demoitié

http://www.w3.org/2001/XMLSchema#string

Marie-Claude Dubois

http://www.w3.org/2001/XMLSchema#string

P304

1543-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2369295

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(07)61542-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

9598

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

Pedro L. Alonso

Arnoldo Barbosa

Inacio Mandomando

W Ripley Ballou

P577

2007-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17949807

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial